These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pharmacological interventions for spasticity following spinal cord injury. Taricco M; Adone R; Pagliacci C; Telaro E Cochrane Database Syst Rev; 2000; 2000(2):CD001131. PubMed ID: 10796750 [TBL] [Abstract][Full Text] [Related]
24. Muscle relaxants for pain management in rheumatoid arthritis. Richards BL; Whittle SL; Buchbinder R Cochrane Database Syst Rev; 2012 Jan; 1():CD008922. PubMed ID: 22258993 [TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin should be first-line treatment for poststroke spasticity. Sheean G J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):359. PubMed ID: 19289475 [No Abstract] [Full Text] [Related]
26. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy]. Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763 [TBL] [Abstract][Full Text] [Related]
27. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Paisley S; Beard S; Hunn A; Wight J Mult Scler; 2002 Aug; 8(4):319-29. PubMed ID: 12166503 [TBL] [Abstract][Full Text] [Related]
28. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Smolenski C; Muff S; Smolenski-Kautz S Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449 [TBL] [Abstract][Full Text] [Related]
30. Anticholinergics for urinary symptoms in multiple sclerosis. Nicholas RS; Friede T; Hollis S; Young CA Cochrane Database Syst Rev; 2009 Jan; (1):CD004193. PubMed ID: 19160231 [TBL] [Abstract][Full Text] [Related]
31. Drug treatments for spasticity. Yelnik AP; Simon O; Bensmail D; Chaleat-Valayer E; Decq P; Dehail P; Quentin V; Marque P; Parratte B; Pellas F; Rousseaux M; Trocello JM; Uzzan M; Dumarcet N; Ann Phys Rehabil Med; 2009 Dec; 52(10):746-56. PubMed ID: 19892619 [No Abstract] [Full Text] [Related]
32. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128 [TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Watts C; Nye C; Whurr R Clin Rehabil; 2006 Feb; 20(2):112-22. PubMed ID: 16541931 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Ade-Hall RA; Moore AP Cochrane Database Syst Rev; 2000; (2):CD001408. PubMed ID: 10796784 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462 [TBL] [Abstract][Full Text] [Related]
36. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Ashworth NL; Satkunam LE; Deforge D Cochrane Database Syst Rev; 2006 Jan; (1):CD004156. PubMed ID: 16437474 [TBL] [Abstract][Full Text] [Related]
37. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Elia AE; Filippini G; Calandrella D; Albanese A Mov Disord; 2009 Apr; 24(6):801-12. PubMed ID: 19224614 [TBL] [Abstract][Full Text] [Related]